Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,625 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Genetics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Alcohol and Implicit Process in Sexual Risk Behavior in MSM

NCT03361384
View directory record Official record
Conditions
Alcohol Drinking, Sex Behavior, Men
Interventions
Alcohol, Placebo (non-alcoholic beverage)
Drug · Other
Lead sponsor
Syracuse University
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • Syracuse, New York • Vermillion, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Curcumin in Treating Patients With Familial Adenomatous Polyposis

NCT00641147
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Curcumin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

NCT04458935
View directory record Official record
Conditions
Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
7 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Withdrawn Phase 2 Interventional

Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04845035
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452
View directory record Official record
Conditions
Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions
oCRH
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
1,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Recruiting No phase listed Observational

InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

NCT05929976
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Nutrition Aspect of Cancer, Microtia, Genetic Predisposition
Interventions
No intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
3 Years to 18 Years
Enrollment
4,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational

Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001

NCT00954655
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
mutation analysis, polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting No phase listed Observational

Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes

NCT02371135
View directory record Official record
Conditions
Lynch Syndrome, Hereditary Colonic Polyposis Syndromes
Interventions
colonic biopsies, questionnaires
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
View directory record Official record
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Interventions
Bone Marrow Aspiration and Biopsy, Trametinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

NCT00010114
View directory record Official record
Conditions
Central Nervous System Embryonal Neoplasm
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 2 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

NCT05877404
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Surveys
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing

NCT03406208
View directory record Official record
Conditions
Neurofibromatoses, Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis
Interventions
Stress and Symptom Management Program 1, Stress and Symptom Management Program 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT03779854
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Bone Marrow Transplantation, Tacrolimus, Methotrexate, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Radiation · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 26 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer

NCT01013129
View directory record Official record
Conditions
Hereditary Prostate Cancer, Prostate Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, evaluation of cancer risk factors, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
21 Years to 120 Years · Male only
Enrollment
748 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Genetic Navigation Engagement Specialists to Increase Knowledge About Colorectal Cancer Genetics in Hispanic/Latino/a Communities

NCT07276048
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Discussion, Educational Intervention, Interview, Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study

NCT04978350
View directory record Official record
Conditions
Lynch Syndrome
Interventions
Educational Workbook
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

NCT04045613
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional Results available

Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions

NCT01457196
View directory record Official record
Conditions
Neoplasm
Interventions
Tumor Genetic Sequencing
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

NCT01392170
View directory record Official record
Conditions
Leukemia
Interventions
PEG-IFNá-2a
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

NCT02160041
View directory record Official record
Conditions
Solid Tumor, Hematologic Malignancies
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Oceanside, California • San Francisco, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment for Lifting Upper Arm Lax Skin

NCT05358327
View directory record Official record
Conditions
Lax Skin
Interventions
Sofwave
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
35 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Sacramento, California • Lincolnshire, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 30, 2026, 1:23 PM EDT